Foresight Diagnostics to Participate in the Jefferies
| Source: Foresight Diagnostics, Inc.
BOULDER, Colo., May 12, 2025 (GLOBE NEWSWIRE) -- Foresight Diagnostics, Inc. (“Foresight”) a leading diagnostics company specializing in the development of ultra-sensitive minimal residual disease (MRD) detection, today announced that Jake Chabon, PhD, Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference on June 3 – 5, 2025 in New York City.
Foresight Diagnostics will be available for 1x1 meetings on June 3rd and 4th. To schedule a meeting, please contact Patrick Charles at LifeSci Advisors, [email protected].
Foresight Diagnostics is a privately held cancer diagnostics company and CLIA-registered laboratory. Its liquid biopsy platform, Foresight CLARITY™, is a novel assay that measures minimal residual disease (MRD) with reported detection limits in parts per million. The improved sensitivity of Foresight CLARITY™ has the potential to provide actionable information to physicians and biopharmaceutical companies to enable more personalized treatment approaches for patients with solid tumor and hematologic malignancies. For more information, please visit foresight-dx.com and follow us on X, LinkedIn, and Bluesky. Foresight CLARITY™ IUO is an investigational device. Limited by United States Law to investigational use.
Sara Head
[email protected]
[email protected]
